An analyst from Wedbush initiated coverage of Sarepta (NASDAQ: SRPT) at 'outperform' with a price target of $224.00. Prior to this rating, Sarepta had 14 buy ratings, 5 hold ratings,...
"Accordingly, as these patients have already commenced treatment, Sarepta Therapeutics has committed, as per the communication received by the NDRC (National Rare Diseases' Committee), to...
Sarepta Therapeutics (SRPT) is seeing upside action Monday (+3.6%) following last week's massive 37% sell-off after a study of DMD drug ELEVIDYS did't reach statistical significance versus...
Sarepta Therapeutics (NASDAQ:SRPT) reported a profitable third quarter in 2023, with a significant increase in total net product revenue, led by the positive impact of their therapy...
An analyst from TD Cowen maintained Sarepta (NASDAQ: SRPT) at 'outperform' with a price target of $115.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
An analyst from Needham & Company maintained Sarepta (NASDAQ: SRPT) at 'buy' with a price target of $93.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Cantor Fitzgerald maintained Sarepta (NASDAQ: SRPT) at 'neutral' with a price target of $80.00 from a prior price target of %currency%%price%. Prior to this rating,...
Investing.com - Sarepta (NASDAQ: SRPT) reported third quarter EPS of $-0.46, $0.76 better than the analyst estimate of $-1.22. Revenue for the quarter came in at $331.8M versus the...
The NASDAQ 100 Pre-Market Indicator witnessed a downturn on Tuesday, with notable shifts in several stocks including ProShares UltraPro Short QQQ (NASDAQ: SQ), Sarepta Therapeutics, Inc....
An analyst from BofA Securities maintained Sarepta (NASDAQ: SRPT) at 'neutral' with a price target of $164.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Morgan Stanley maintained Sarepta (NASDAQ: SRPT) at 'overweight' with a price target of $146.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from JPMorgan maintained Sarepta (NASDAQ: SRPT) at 'overweight' with a price target of $115.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
(Updated - October 31, 2023 7:13 AM EDT) Sarepta Therapeutics (NASDAQ:SRPT) Resumes Trading, Down 40% In EMBARK, participants treated with ELEVIDYS (delandistrogene moxeparvovec-rokl)...
(Updated - October 31, 2023 6:54 AM EDT) Analysts at Oppenheimer downgraded Sarepta Therapeutics (SRPT) from Outperform to Perform.The analysts comment: "Sarepta reported Phase 3 results...
An analyst from Baird maintained Sarepta (NASDAQ: SRPT) at 'outperform' with a price target of $136.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta had...
An analyst from RBC Capital maintained Sarepta (NASDAQ: SRPT) at 'outperform' with a price target of $148.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
An analyst from Evercore ISI maintained Sarepta (NASDAQ: SRPT) at 'in line' with a price target of $94.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
An analyst from Cantor Fitzgerald downgraded Sarepta (NASDAQ: SRPT) from 'overweight' to 'neutral' with a price target of $40.00 from a prior price target of %currency%%price%. Prior to...
After-Hours Stock Movers:Lattice Semiconductor (LSCC) 16% LOWER; reported Q3 EPS of $0.53, $0.01 better than the analyst estimate of $0.52. Revenue for the quarter came in at $192.17 million...
(Updated - October 30, 2023 4:20 PM EDT) Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced topline results from...
Sarepta Therapeutics (SRPT) Halted, News Pending
An analyst from Mizuho Securities maintained Sarepta (NASDAQ: SRPT) at 'buy' with a price target of $160.00. Prior to this rating, Sarepta had 15 buy ratings, 3 hold ratings, and 0 sell...
Quest Diagnostics (NYSE:DGX) announced that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Breakthrough...
Investing.com -- Here is your Pro Recap of the biggest insider trades and institutional investor headlines you may have missed last week: news out of |Starboard Value LP and Bloomin Brands, ...
In a Form 4 filing with the SEC today, Sarepta Therapeutics (SRPT) director, Michael Andrew Chambers, disclosed the purchase of 23,686 common shares made on 08/11/23 at $108.05 per share.The...
Sarepta Therapeutics (SRPT) Trades at High, Up 4%
An analyst from UBS maintained Sarepta (NASDAQ: SRPT) at 'buy' with a price target of $174.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta had 16 buy...
An analyst from RBC Capital maintained Sarepta (NASDAQ: SRPT) at 'outperform' with a price target of $223.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
An analyst from Credit Suisse maintained Sarepta (NASDAQ: SRPT) at 'neutral' with a price target of $139.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
Investing.com - Sarepta (NASDAQ: SRPT) reported second quarter EPS of $-0.85, $0.92 better than the analyst estimate of $-1.77. Revenue for the quarter came in at $261.2M versus the...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority...
An analyst from JPMorgan maintained Sarepta (NASDAQ: SRPT) at 'overweight' with a price target of $213.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
An analyst from Evercore ISI downgraded Sarepta (NASDAQ: SRPT) from 'outperform' to 'in line' with a price target of $139.00. Prior to this rating, Sarepta had 17 buy ratings, 3 hold...
An analyst from Citi maintained Sarepta (NASDAQ: SRPT) at 'buy' with a price target of $161.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta had 17 buy...
An analyst from Goldman Sachs maintained Sarepta (NASDAQ: SRPT) at 'buy' with a price target of $215.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta had...
An analyst from BofA Securities maintained Sarepta (NASDAQ: SRPT) at 'buy' with a price target of $185.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
An analyst from Barclays maintained Sarepta (NASDAQ: SRPT) at 'overweight' with a price target of $193.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
Sarepta Therapeutics (SRPT) to Resume Trading at 2:20 p.m.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS...
Sarepta Therapeutics (SRPT) Halted, News Pending
An analyst from Evercore ISI maintained Sarepta (NASDAQ: SRPT) at 'outperform' with a price target of $151.00 from a prior price target of %currency%%price%. Prior to this rating,...
Investing.com -- Stocks are falling on Wednesday as negotiations on the debt ceiling dragged on with the deadline swiftly approaching. Here are the market movers for May 24. Abercrombie &...
An analyst from Credit Suisse maintained Sarepta (NASDAQ: SRPT) at 'neutral' with a price target of $141.00 from a prior price target of %currency%%price%. Prior to this rating, Sarepta...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
